Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810105 · ClinicalTrials.gov registry record · Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03810105: Clinical Trial Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03810105 is a Phase 2 study that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810105, a Phase 2 study, was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
Primary Outcome
To assess the therapeutic efficacy as defined by an undetectable PSA (\<0.05 or PSA \<0.10 for institutions where this is the lower limit of detection) with non-castrate levels of testosterone using the combination olaparib (PARP inhibition) with durvalumab (PDL1 inhibition) at 24 months (cycle 24) in biochemically recurrent prostate cancer
Interventions
- DRUG Olaparib
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-03-07 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 2 |
Why NCT03810105 stopped before completion
NCT03810105 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT03810105 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03810105 about?
NCT03810105 is a clinical study titled "A Study of Olaparib and Durvalumab in Prostate Cancer". The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
What is the current status of trial NCT03810105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-03-07. Estimated completion is 2023-07-06.
What interventions are being tested in trial NCT03810105?
The interventions under investigation include: Olaparib (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03810105?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03810105's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI